Current position

Ray Dalio’s Harmony Biosciences Hldgs In (HRMY) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Bridgewater Associates, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2025Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares251.51KHighest verified quarter-end share count
Quarters reported4Verified quarters with shares above zero
What happened?

Bridgewater Associates, LP first reported Harmony Biosciences Hldgs In in Q3 2025. The reported position was increased and reduced across later filings. Bridgewater Associates, LP currently reports 248.58K shares. The latest verified filing showed: Sold 1.2% of the position.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Sold 1.2% of the position−2.93K shares · 248.58K shares remained
Filing context

Quarter-end price $36.41 · Estimated holding basis $28.27

Q1 2026
Bought 10.1% more+22.99K shares · 251.51K shares reported after the change
Filing context

Quarter-end price $28.01 · Estimated holding basis $28.27

Q4 2025
Bought 8.0% more+16.99K shares · 228.51K shares reported after the change
Filing context

Quarter-end price $37.42 · Estimated holding basis $28.29

Q3 2025
New position+211.53K shares · 211.53K shares reported
Filing context

Quarter-end price $27.56 · Estimated holding basis $27.56

Portfolio importance

How important is Harmony Biosciences Hldgs In in Bridgewater Associates, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.0%Q2 2026
Current rank#353of 997 reported positions
Peak portfolio weight0.0%Q2 2026
Best historical rank#340Q1 2026
At peak importanceQ2 2026
HRMY
0.0%
Largest holding
16.3%
Cross-investor discovery

Who else owns Harmony Biosciences Hldgs In?

Also reported by 1 other tracked investor in their latest verified filings.

Joel GreenblattGotham Asset Management
HRMY0.0% of reported portfolio
Explore Harmony Biosciences Hldgs In across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$41.542026-09-14

Market context only; not an investor transaction price.

Latest filing quarter-end price$36.41Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$28.27Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Bridgewater Associates, LP’s Form 13F disclosures, not Ray Dalio’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.